Kurma Partners

𝗞𝘂𝗿𝗺𝗮 𝗛𝗥  : 🧬 𝗝𝗼𝗶𝗻 𝘁𝗵𝗲 𝗞𝘂𝗿𝗺𝗮 𝗕𝗶𝗼𝗳𝘂𝗻𝗱 𝗧𝗲𝗮𝗺 | 𝗜𝗻𝘁𝗲𝗿𝗻𝘀𝗵𝗶𝗽 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 We’re looking for a curious and motivated intern to join 𝘁𝗵𝗲 𝗞𝘂𝗿𝗺𝗮 𝗕𝗶𝗼𝗳𝘂𝗻𝗱 𝘁𝗲𝗮𝗺 𝗶𝗻 𝗣𝗮𝗿𝗶𝘀 starting 𝗝𝗮𝗻𝘂𝗮𝗿𝘆 𝟮𝟬𝟮𝟲 for 𝗮 𝟲-𝗺𝗼𝗻𝘁𝗵 𝗶𝗻𝘁𝗲𝗿𝗻𝘀𝗵𝗶𝗽. Kurma Partners has been transforming healthcare through innovation since 2009, investing in 𝗕𝗶𝗼𝘁𝗲𝗰𝗵, 𝗛𝗲𝗮𝗹𝘁𝗵𝘁𝗲𝗰𝗵, 𝗮𝗻𝗱 𝗧𝗲𝗰𝗵𝗯𝗶𝗼 companies across Europe. As part of the Biofund team, you’ll gain hands-on experience 𝗶𝗻 𝗲𝗮𝗿𝗹𝘆-𝘀𝘁𝗮𝗴𝗲 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝘃𝗲𝗻𝘁𝘂𝗿𝗲 𝗰𝗮𝗽𝗶𝘁𝗮𝗹, contributing to deal sourcing, due diligence, investment memos, and portfolio support. 🔹 𝗪𝗵𝗼 𝘄𝗲’𝗿𝗲 𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝗳𝗼𝗿 ·      MSc or PhD background in Life Sciences ·      Genuine interest in drug development, biotech entrepreneurship, and venture capital ·      Analytical, proactive, and collaborative mindset 📍 𝗟𝗼𝗰𝗮𝘁𝗶𝗼𝗻: Paris 🗓 𝗦𝘁𝗮𝗿𝘁 𝗱𝗮𝘁𝗲: January 2026 If you’re passionate about translating science into real-world impact, we’d love to hear from you. 📩 Apply by sending your CV and a short paragraph about yourself to [email protected] #Biotech #VentureCapital #LifeSciences #Internship #Innovation #KurmaPartners

Grateful to have supported ImCheck Therapeutics from day one Proud of the journey accomplished together, thank you to Pierre d'Epenoux and the ImCheck Therapeutics team for their trust and collaboration throughout the years. #ImmunoOncology #Biotech #KurmaPartners

𝑲𝒖𝒓𝒎𝒂 𝑷𝒐𝒓𝒕𝒇𝒐𝒍𝒊𝒐 𝑵𝒆𝒘𝒔🚀 : We're thrilled to announce the acquisition of ImCheck Therapeutics, a company of Kurma Partners and Eurazeo portfolio by Ipsen for up to €1Bi including €350M upfront payment. Kurma has been founder investor and has supported ImCheck since its early days. This transaction follows the sale, among others, of Corlieve Therapeutics to UniQure, Emergence Tx to Eli Lilly and Amolyt Pharma to AstraZeneca, and confirms the success of Kurma Partners' business model. 👏 Kudos to Daniel Olive, scientific founder for this new success after Emergence, amazing Track record!! and congrats to Pierre d'Epenoux, all ImCheck team and our co-investor Andera Partners, Bpifrance, PFIZER INC., Gimv, EQT Life Sciences,Earlybird Venture Capital, Wellington Partners,Pureos Bioventures,Invus, Agent Capital, and Boehringer Ingelheim for this great success Stephan Braun, Claude Knopf, @hans henrik Christensen, Thomas Civik Rémi Droller #biotech #pharma #lifesciences #successstory #M&A #healthcare

𝑷𝒐𝒓𝒕𝒇𝒐𝒍𝒊𝒐 𝒏𝒆𝒘 𝒊𝒏𝒗𝒆𝒔𝒕𝒎𝒆𝒏𝒕 :  We’re proud to co-lead Adcytherix’s €105 million Series A, led by Bpifrance, alongside Andera Partners and Angelini Ventures, to support the company’s next stage of growth. The proceeds will enable Adcytherix to advance its lead program, ADCX-020, into the clinic and accelerate the development of innovative ADC programs using novel payloads - marking an important step forward in the field of antibody-drug conjugates (ADCs). Congratulations to the entire Adcytherix team and all our co-investors - Bpifrance, Andera Partners, Angelini Ventures, Surveyor Capital, aMoon Fund, and existing shareholders Pontifax Venture Capital, Dawn Biopharma, Pureos Bioventures, and RA Capital - on this milestone! More information on : https://lnkd.in/e4ieWmJJ #Biotech #VentureCapital #LifeSciences #KurmaPartners #ADCs #Innovation

Exciting Milestone for Step Pharma. Kurma is thrilled to announce that Step Pharma has successfully completed a €38M financing round to accelerate the development of its novel and firt in class CTPS1 inhibitor. Kurma Partners has been founder investor of Step Pharma and continues to support the development of the company alongside other existing investors and V-Bio Ventures as new investor in this new financing Congrats to Andy Parker and all Step Pharma team for this great achievement Philip Beer, Maureen Higgins, Nicolas Marsault, Thien Duc Tran #biotech #venturecapital #venture #biopharma #pharma

Kurma Press : In this recent PharmaBoardroom article, Rémi Droller, Managing Partner at Kurma, shares our perspective on 𝗗𝗲𝗻𝗺𝗮𝗿𝗸’𝘀 𝗿𝗮𝗽𝗶𝗱𝗹𝘆 𝗺𝗮𝘁𝘂𝗿𝗶𝗻𝗴 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗲𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺 and explains how 𝗞𝘂𝗿𝗺𝗮’𝘀 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗺𝗼𝗱𝗲𝗹  combines 𝗲𝗮𝗿𝗹𝘆-𝘀𝘁𝗮𝗴𝗲 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝗰𝗿𝗲𝗮𝘁𝗶𝗼𝗻 with 𝗹𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝗴𝗿𝗼𝘄𝘁𝗵 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 across a pan-European platform. Despite some structural challenges, we remain convinced that 𝘁𝗵𝗲 𝘀𝗲𝗲𝗱𝘀 𝗼𝗳 𝗘𝘂𝗿𝗼𝗽𝗲’𝘀 𝗻𝗲𝘅𝘁 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝘀𝘂𝗰𝗰𝗲𝘀𝘀 𝘀𝘁𝗼𝗿𝗶𝗲𝘀 𝗮𝗿𝗲 𝗮𝗹𝗿𝗲𝗮𝗱𝘆 𝗯𝗲𝗶𝗻𝗴 𝗽𝗹𝗮𝗻𝘁𝗲𝗱. We hope you find it insightful. #Denmark #DanishBiotech #LifeSciences #HealthcareInnovation #VentureCapital #EuropeanInnovation #StartupEcosystem https://lnkd.in/egPi_nTG

🚨HR Opportunity 🚨: Kurma Partners recherche un(e) Compliance Officer (Associate) pour rejoindre son équipe à Paris (Place de la Madeleine). 🎯 Vos missions (en support et collaboration directe avec la RCCI) : - Participer au plan de contrôle interne et à la cartographie des risques - Réaliser des tests et contrôles de second niveau - Contribuer à la veille réglementaire (AMF, ESG, etc.) et aux reportings - Sensibiliser et accompagner les équipes sur les enjeux de conformité 👤 Profil recherché : - Bac+4/5 en droit, finance, audit ou gestion des risques - 1 à 3 ans d’expérience en conformité, audit ou contrôle interne - Esprit d’analyse, rigueur, autonomie et sens de la confidentialité - Bonne maîtrise de l’anglais ✨ Pourquoi nous rejoindre ? - Collaboration directe avec la RCCI et forte exposition aux équipes opérationnelles - Environnement stimulant, à taille humaine - Poste clé dans la structuration d’un dispositif de conformité moderne et agile 📩 Intéressé(e) ? Envoyez votre candidature à [email protected] #Compliance #ContrôleInterne #AssetManagement #PrivateEquity #Recrutement

Kurma portfolio New Investment : We are happy to announce that the Kurma Growth Opportunities Fund co-led the €84M Series B financing round of NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform. We believe that NUCLIDIUM’s differentiated platform, leveraging Copper-61 for diagnostics and Copper-67 for therapeutics, is very well positioned to address current limitations in radiotheranostics, such as suboptimal clinical efficacy and complex manufacturing. This financing round was supported by a strong European syndicate of life sciences investors, including Angelini Ventures, Wellington Partners, NEVA SGR (Intesa San Paolo Group), DTCF | DeepTech & Climate Fonds (DTCF), Bayern Kapital, Eurazeo, VIVES Partners, NRW.BANK HighLight Capital. We are proud to support NUCLIDIUM’s mission and look forward to contributing to the company’s continued growth. Congratulations to the entire NUCLIDIUM team and a warm welcome to the Kurma Growth Opportunities Fund portfolio Click on the following link to learn more: https://lnkd.in/eViMwGtW Congratulation to all the Nuclidium's team : Leila Jaafar, Tony Rosenberg David Meek Oliver Sartor Bela Denes Gary Ulaner Daniel Parera Jean-Francois Rivassou Maÿlis Deschamps #Radiopharmaceuticals #Biotech #CopperTheranostics

Kurma Portfiolio New Investment : We’re proud to announce our investment in EvlaBio, a pioneering biotech company developing a first-in-class monoclonal antibody to treat left ventricular hypertrophy (LVH) in the context of chronic kidney disease (CKD). 👏 A warm congratulations to the entire EvlaBio team for their outstanding work and vision. We're thrilled to support such a highly innovative and impactful approach in the cardio-renal space, alongside great co-investors: AdBio partners, Boehringer Ingelheim Venture Fund, @NRW.Venture (NRW.BANK), and HTGF | High-Tech Gründerfonds. More information : https://lnkd.in/eViMwGtW

Kurma News : 💡 Big step forward for mental health innovation! We’re proud to announce the €11.25M seed round of Elkedonia, a new biotech company pioneering the development of first-in-class neuroplastogens for treatment-resistant depression and other neuropsychiatric disorders. 🎯 Non-addictive, non-hallucinogenic, and rapid-acting molecules targeting novel intracellular mechanisms (Elk1) — a promising alternative to psychedelics and ketamine. 🚀 Elkedonia is a spin-off from Argobio, based on groundbreaking research from Sorbonne Université and supported by a strong European syndicate of life sciences investors WE Life Sciences, Bpifrance,Angelini Ventures, CARMA FUND Management GmbH, Capital Grand Est, and Sambrinvest. Congratulations to Delphine Charvin, newly appointed CEO, and the whole Elkedonia team! 👉 Learn more: www.elkedonia.com #MentalHealth #Neuroscience #Biotech #VC #KurmaPartners #Neuropsychiatry #Innovation #LifeSciences